May 2nd - 4th, 2018

Paris, France

#GMTCC

2018 Programme - Paris

Sessions are tentative and subject to change. Last update: 14 December 2017

2 May

10.45 - 13.00

MedTech Europe Ethics & Compliance Committee (ECC) Meeting (MEMBERS ONLY)
(Napoleon Room)

AdvaMed DDCG Meeting (Members ONLY)
(Concorde Ballroom)

SME Compliance Bootcamp (in French) – to be confirmed
(Aiglon Room)

13.00 - 14.00Lunch ECC-DDCG-SME Bootcamp
(Imperial Room)
14.00 - 15.45

MedTech Europe Ethics & Compliance Committee (ECC) Meeting (MEMBERS ONLY) - continuation
(Napoleon Room)

AdvaMed DDCG Meeting (Members ONLY) - continuation
(Concorde Ballroom)

SME Bootcamp - continuation - to be confirmed
(Aiglon Room)

16.00 - 17.30Joint ECC-DDCG Meeting
(Concorde Ballroom)
18.00 - 19.30Welcome Reception & PwC Compliance Achievement Award Sponsored by PwC
(Imperial Room)

3 May

8.00 - 9.15

Breakfast meeting for Healthcare Organisations & Professionals Conference Organisers 

09.30 - 10.15

Opening Panel
(Concorde Ballroom)

Moderator: Ingmar de Gooijer (invited)

Speakers:

  • Michelle Brennan, Company Group Chair, Medical Devices EMEA, Johnson & Johnson and Chairwoman of the MedTech Europe's Board of Directors (confirmed)
  • Nadim Yared, CEO of CVRx and Chairman of AdvaMed's Board of Directors (invited)

Description: The two associations’ Chairs will discuss the MTE & AdvaMed priorities, including the key priority of Code compliance and how this topic underpins all other themes addressed by industry. Issues such as Code convergence will also be addressed.

10.15 - 10.45

Keynote Speech - Considerations for industry
(Concorde Ballroom)

  • Charles Duchaine, Director,  French Anti-corruption Agency (AFA) (invited)
10.45 - 12.15

Plenary 1 - “HealthTech – what does it mean for compliance?”
(Concorde Ballroom)

Speakers:

Moderator: Ingmar de Gooijer

Description: HealthTech could be defined as the use of technology (e.g. databases, applications, services, mobiles, wearables) to improve the delivery, payment, and/or consumption of care, with the ability to increase the development and commercialization of more traditional MedTech products. For companies, the implications are profound, and these new commercial models present opportunities but also significant challenges and there is also a every growing set of regulatory guidelines, which are often outdated before they enter into force.What does this change mean for the compliance function? The discussion is much broader than only privacy as these are new business models, with new risks such as corruption/inducement; direct interactions with patients; competition law and tax aspects.

15.15 - 16.00Networking lunch
(Imperial-Aiglon Room)
13.30 - 15.00

Parallel Session 1: Legal & Compliance Risks of Public-Private Partnerships
(Napolean Room)

Moderator

Speakers:

Description: Governments all over the world, but in particular in high growth markets, encounter budget restrictions, but at the same time they want to compete to further improve quality of care, access to innovation and expertise. One model that these governments are therefore looking at are Healthcare Public Private Partnerships (PPP), but the number of actual projects is still limited and so are the lessons learned. Banking on existing expertise, the panel will discuss the legal and compliance risks of such PPPs.

Parallel Session 2: Distributor compliance: can have, wanna have, must have?
(Vendome Room)

Moderator:

Speakers:

Description: This panel aims at discussing the regulatory changes in their broadest sense and what this means from distributors and their relationship with MedTech companies, considering the different types of relationships that exist. In addition, the Panel will review to how to meet mutual expectations, through innovative means (e.g. “Compliance in the Box programs”). 

Parallel Session 3: Leveraging Governmental Affairs strategies to drive compliance objectives
(Tuileries Room)

Moderator:

Speakers:

Description: This session is designed as a brainstorming session in order to discuss how industry can be more effective in shaping national legislation to avoid legislation which is not fit for purpose from a compliance perspective (e.g. transparency laws). Aspects such collaboration between Public Affairs and Compliance teams shall be addressed as well.

15.00 - 15.30

Networking Break
(Imperial-Aiglon Room)

15.30 - 17.15

Ask the Experts session
(Concorde Ballroom)

Main Moderator:

Description: This session will be set up in roundtable discussions. The time allocated will allow them to get to the heart of key issues. Attendance is limited to 12 persons per table. After 40 minutes, the participants are invited to switch tables. Each table lead will prepare in advance a one-pager with key topics/trends that they plan to address. After the discussions, key discussion points/outcome will be added to this one-pager and circulated to all participants.

Topics & Table Leads:

  • Applying the MTE Code in France: Olivier Sudre (J&J) (confirmed)
  • China
  • GDPR / Privacy
  • MTE Transparancy: Pablo Abad, Legal & Compliance Manager, MedTech Europe (MTE) (confirmed)
18.00 - 19.30

Welcome reception

20.00 - 22.30

GMTCC Networking Dinner

Sponsor:

4 May

8.00 - 9.00Registration & Welcome Coffee
(Imperial-Aiglon Room)
09.00 - 10.15

Plenary 2: Multi-disciplinary panel
(Concorde Ballroom)

Speakers:

Moderator: Ingmar de Gooijer

Description: This panel will examine the role of compliance officer through the perspective of different Compliance Officers of organisations such as MedTech/pharma company; Distributor; Hospital. The speakers will also share their perspectives on their key challenges and discuss the common elements as well as differences of their respective jobs.

10.15 - 10.45Networking break
(Imperial-Aiglon Room)
11.00 - 12.30

Parallel Session 1: Exchange of best practices on Educational Grants around the world
(Napoleon Room)

Speakers:

Moderator:

Description: With the phase out of Direct Sponsorship across which came into force in many jurisdictions across the world at the beginning of the year, companies are learning how to structure their educational strategies as well as processes around Educational Grants. This panel will provide insights as to what has worked and not works for different players in different jurisdictions around the world.

Parallel Session 2: 
(Vendome Room)

Speakers:

Moderator:

Description

Parallel Session 3: Are the seven FCPA elements enough?
(Tuileries Room)

Speakers:

Moderator:

Description: recent European legislators seem to have gone a step further then the DOJ in regulating what they expect a good compliance program to be. This panel will start with mapping some of the recent legislations and then discuss how to ensure that the company complies with all these requirements.

12.30 - 13.45

Networking Lunch
(Imperial-Aiglon Room)

13.45 - 15.30

Plenary session 3: What is the value of compliance?
(Concorde Ballroom)

Moderator: Ingmar de Gooijer

Speakers:

  • Erin Walsh is the new Assistant Secretary of Commerce for Global Markets (GM) and Director General of the U.S. and Foreign Commercial Service (CS) (invited)

Description: This panel will discuss what the perception of stakeholders is on MedTech industry’s brand equity. Have codes changed stakeholders’ perception(s)? Furthermore, the discussion should address what the value of compliance is, for a country, for patients, for a healthcare system and also for a company (e.g. which KPIs and is the absence of consequences enough?).

15.30 - 15.45

Plenary session: Closing remarks & discussions
(Concorde Ballroom)

Moderator: Ingmar de Gooijer

Speakers:

  • Roeland Van Aelst, VP Healthcare Compliance EMEA & Canada, Johnson & Johnson and chairman of the MTE Ethics & Compliance Committee (invited)
  • Bronwen Taylor, Vice President, Compliance & Risk Management, Stryker and chairwoman of the AdvaMed DDCG (invited)